AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17013479
Drug: No medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medications (control group)
Trial: 15464863
Drug: drugs +
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drugs + rTMS (1 Hz, 0.6 T, 100 stimuli per day for 7 days, repeated at least twice yearly for 3 years)
Trial: 15461603
Drug: drugs only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drugs only
Trial: 11417923
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + Melatonin
Trial: 19419845
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + Placebo
Trial: 9236640
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg rhRIx
Trial: 9236640
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg rhRIx
Trial: 9236640
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg rhRIx
Trial: 8783319
Drug: Naloxone (opiate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (opiate antagonist)
Trial: 25052161
Drug: YXBCM01 granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YXBCM01 granule (5.5 g twice daily)
Trial: 25052161
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy (calcipotriol betamethasone for the first 4 weeks and calcipotriol ointment for the remaining 8 weeks)
Trial: 12100060
Drug: prednisolone 30
RxNorm normalized name: prednisolone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone 30 mg/day
Trial: 7717714
Drug: 5‐fluorouracil (5‐FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU) 600 mg/m2 plus high‐dose l‐leucovorin (l‐LV) 250 mg/m2, given weekly by i.v. injection
Trial: 7717714
Drug: 5‐fluorouracil (5‐FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU) 370 mg/m2 plus high‐dose l‐leucovorin (l‐LV) 100 mg/m2, given simultaneously for 5 consecutive days
Trial: 7717714
Drug: 5‐fluorouracil (5‐FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU) 370 mg/m2 plus low‐dose l‐leucovorin (l‐LV) 10 mg/m2, given with the same schedule as regimen B
Trial: 1790311
Drug: Pentacard 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentacard 20 mg tablets
Trial: 1790311
Drug: Ismo 20
RxNorm normalized name: Ismo 20mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ismo 20 mg tablets
Trial: 30826050
Drug: No loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No loading dose (NLD)
Trial: 30826050
Drug: Clopidogrel maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel maintenance therapy
Trial: 30826050
Drug: No clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No clopidogrel maintenance therapy
Trial: 28827938
Drug: Honey (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey (20 mL)
Trial: 10791216
Drug: Mannite solution
RxNorm normalized name: Mannit
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannite solution (10%); 2000 mL during the first 2 hours, then 2000 mL per day until no rectal blood observed.
Trial: 10791216
Drug: Paromomycine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycine (1 g tid) and lactulose (10 mL tid)
Trial: 8876703
Drug: Atamestane 300
RxNorm normalized name: Atamestane
DrugBank: Atamestane (DB12194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atamestane 300 mg
Trial: 1496141
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy (20 Gy in 10 treatments over 2 weeks)
Trial: 26717873
Drug: Nurse-initiated daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-initiated daily verbal reminders
Trial: 24727333
Drug: Dexamethasone 0.1
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.1 mg/mL
Trial: 21054769
Drug: 320/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320/25 mg valsartan/hydrochlorothiazide (HCTZ)
Trial: 17425487
Drug: Control (currently
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (currently approved treatment options)
Trial: 10540089
Drug: Remifentanil with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil with propofol (target plasma concentration of remifentanil varied while maintaining propofol at 4.5 microg x ml-1)
Trial: 18057912
Drug: Clotrimazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (100 mg)
Trial: 31082898
Drug: Somatostatin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (500 μg bolus followed by 250 μg/h infusion for 5 days)
Trial: 21487089
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (atorvastatin 80 mg)
Trial: 16954134
Drug: Standard statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard statin therapy (pravastatin 40 mg)
Trial: 3876325
Drug: sulphamoxole 3200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulphamoxole 3200 mg/trimethoprim 640 mg (single dose)
Trial: 3876325
Drug: trimethoprim 700
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: trimethoprim 700 mg (single dose)
Trial: 3876325
Drug: sulphamoxole 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulphamoxole 800 mg/trimethoprim 160 mg (twice daily for five days)
Trial: 30052825
Drug: S66913 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S66913 (5 mg, 25 mg, or 100 mg orally per day)
Trial: 18049889
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (ganirelix 0.25 mg/d for 3 days)
Trial: 18049889
Drug: Control (self-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (self-controlled cycle without GnRH antagonist)
Trial: 9828907
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with GnRH analogue leuprolide acetate (0.3 mg/kg im every 28 days) and rhGH (0.1 U/kg/day, sc, 6 days a week) for 30.0 ± 5.2 months
Trial: 2894764
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate 50 mg twice a day
Trial: 29327548
Drug: TCM synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM synthetic rehabilitation (manipulative therapy, joint mobilization, soaking-washing with Chinese medicinal herbs, functional exercise)
Trial: 25531733
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 10 mg/kg as a bolus, 15 minutes before incision
Trial: 17158419
Drug: High-fructose diet
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fructose diet (1.5 g fructose . kg body wt(‐1) . d(‐1) for 4 weeks)
Trial: 1582625
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril (E) 20‐40 mg daily
Trial: 29458318
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care oxygen therapy
Trial: 20092401
Drug: Vitamin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin treatment with folic acid and vitamin B12 for 2 months (Group 2, n = 30)
Trial: 19909082
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated split-virus influenza vaccine (TIV)
Trial: 11571068
Drug: Alcohol‐focused couples
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol‐focused couples therapy
Trial: 2881566
Drug: Atracurium (ED95
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (ED95 0.23 mg kg‐1)
Trial: 27489011
Drug: DPZS (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPZS (7 mg Zn/d)
Trial: 19457494
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine (40 mL)
Trial: 31242943
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (MTX)
Trial: 6179339
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of long-term continuous steroid application
Trial: 29617743
Drug: Head orthosis
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head orthosis therapy
Trial: 2928987
Drug: Sodium excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium excretion
Trial: 18789189
Drug: Body oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body oriented psychological therapy (BPT)
Trial: 15062138
Drug: Chemotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy or hyperthermia
Trial: 15062138
Drug: Interstitial pulsed-dose-rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interstitial pulsed-dose-rate (PDR) brachytherapy
Trial: 11032084
Drug: Reference products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference products as per WHO List of International Comparator Pharmaceutical Products (CPP)
Trial: 11032084
Drug: Generic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic drugs developed using the CPP
Trial: 11032084
Drug: Formulations with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations with maintained safety and efficacy
Trial: 9127120
Drug: Blood-volume-pulse biofeedback
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-volume-pulse biofeedback followed by cognitive behavioral therapy (Group I)
Trial: 9127120
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy followed by blood-volume-pulse biofeedback (Group II)
Trial: 1337291
Drug: Naloxone (0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.015 mg/kg)
Trial: 8796815
Drug: Naloxone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (both doses)
Trial: 1337291
Drug: Naloxone (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (low dose)
Trial: 27098820
Drug: Stepwise implementation
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepwise implementation administered and monitored in a quarterly rheumatological nurse‐administered set‐up targeting hyperlipidaemia, hypertension, hyperglycaemia, and microalbuminuria
Trial: 19079825
Drug: Carers' critical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carers' critical comments (CC) at follow-up
Trial: 15824508
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (5 doses of 200 mg weekly)
Trial: 10383527
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.d. in H. pylori-negative patients
Trial: 6753092
Drug: Flunisolide (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide (topical corticosteroid)
Trial: 29410968
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (1 g TXA intravenously)
Trial: 29410968
Drug: Topical TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TXA (3 g TXA in 100 ml saline intra-articularly)
Trial: 29410968
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA vs Topical TXA
Trial: 25544738
Drug: Paroxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine treatment for 12 weeks
Trial: 25544738
Drug: Dose-escalation intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-escalation intervention after 6 weeks
Trial: 15536655
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three techniques (NIR, Laser Doppler, Digital photography)
Trial: 8901854
Drug: Alpha-tocopherol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol (50 mg)
Trial: 31306433
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for soil-transmitted helminth infection (specific interventions not detailed in the abstract)
Trial: 28635026
Drug: ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ixekizumab 80 mg every 4 weeks (IXEQ4W)
Trial: 28635026
Drug: ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ixekizumab 80 mg every 12 weeks (IXEQ12W)
Trial: 28635026
Drug: ixekizumab (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ixekizumab (any dosage)
Trial: 23375005
Drug: Physiotherapy (isometric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy (isometric training of abdominal muscles, diaphragmatic breathing exercises, and abdominal massage during 12 40‐min sessions twice a week) + laxatives
Trial: 18678578
Drug: rAAV2‐TNFR:Fc (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV2‐TNFR:Fc (1 x 10(11) DNase resistant particles per ml joint volume)
Trial: 17341245
Drug: Receipt of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receipt of pneumococcal vaccine
Trial: 10336577
Drug: Clevidipine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevidipine at target dose rates ranging from 0.12 to 48 nmol min‐1 kg‐1
Trial: 8760089
Drug: Constant GH
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant GH infusion
Trial: 1744358
Drug: Immunotherapy (IT)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (IT) for 3 and 4 years
Trial: 1744358
Drug: Non-immunotherapy (non-IT)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-immunotherapy (non-IT)
Trial: 27869715
Drug: Inositol-stabilized arginine
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for 14 days
Trial: 27869715
Drug: Inositol-stabilized arginine
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for 3 days
Trial: 27869715
Drug: Inositol-stabilized arginine
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for a 10-min period
Trial: 12140664
Drug: Flupirtine 100
RxNorm normalized name: flupirtine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine 100 mg
Trial: 22940462
Drug: Daily anger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily anger expression in LBP patients
Trial: 15776331
Drug: CHO (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (10% glucose, 30 mmol . l (‐1) NaCl)
Trial: 15776331
Drug: W (water,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: W (water, 30 mmol . l (‐1) NaCl)
Trial: 19563665
Drug: Rectal diazepam
RxNorm normalized name: diazepam Rectal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diazepam
Trial: 1781807
Drug: Cefadroxil plus
RxNorm normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefadroxil plus N-acetylcysteine (1000 mg cefadroxil + 200 mg N-acetylcysteine)
Trial: 1781807
Drug: Cefadroxil alone
RxNorm normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefadroxil alone (1000 mg)
Trial: 6982626
Drug: Thiopentone (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (3.0 mg/kg)
Trial: 6982626
Drug: Althesin (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Althesin (0.07 ml/kg)
Trial: 7125264
Drug: Ketamine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1.5 mg/kg)
Trial: 6982626
Drug: Fentanyl (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.01 mg/kg) added to Althesin and Flunitrazepam
Trial: 6982626
Drug: Fentanyl (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.01 mg/kg) added to Ketamine
Trial: 29652795
Drug: Non-nucleoside reverse
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Trial: 31629649
Drug: Control (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (repeated initial vaccination with HBVaxPro 10 μg or Engerix‐B 20 μg)
Trial: 31629649
Drug: HBVaxPro 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBVaxPro 40 μg
Trial: 22886490
Drug: Autologous pulsed
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous pulsed dendritic cell vaccine
Trial: 8737755
Drug: Intravenous Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Erythropoietin (IV EPO)
Trial: 8737755
Drug: Subcutaneous Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Erythropoietin (SC EPO)
Trial: 1351025
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg once a day
Trial: 1351025
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg a day (50 mg twice a day)
Trial: 6741192
Drug: Daily perseverance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily perseverance training of 60 min at about 50% VO2 max
Trial: 21102473
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) treatment for a mean duration of 1 year
Trial: 21102473
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment or vitamin E
Trial: 16485727
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) treatment
Trial: 19920081
Drug: Patient intervention
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient intervention (20 weekly group sessions followed by 12 monthly telephone counseling contacts focusing on weight loss, DASH dietary pattern, exercise, and reduced sodium intake)
Trial: 25970229
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 0.6 mg/kg with additional doses of 10-20 mg until OAA/S score 2-4
Trial: 8596489
Drug: Trelan G‐75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trelan G‐75 (1,200 mOsm/L, 225 mL) equivalent to 75 g glucose
Trial: 16440531
Drug: Rupatadine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 10 mg once daily
Trial: 29547159
Drug: Pyridoxine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (30 mg/kg/day) with oral prednisolone (4 mg/kg/day)
Trial: 29547159
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (4 mg/kg/day) alone
Trial: 22985607
Drug: Phlebotomy (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebotomy (450 mL, every 2 weeks until serum ferritin levels of 20 ng/mL)
Trial: 17922939
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) group treatment
Trial: 10332014
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment (24 sessions of 15 minutes, frequency 0.89 MHz, intensity 2.5 W/cm², pulsed mode 1:4)
Trial: 30634204
Drug: Rhubarb (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb (80 mg/kg, twice per day) combined with medicinal activated carbon (1.5 g each time, thrice per day) for 8 weeks
Trial: 30634204
Drug: Medicinal activated
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicinal activated carbon (1.5 g each time, thrice per day) for 8 weeks
Trial: 21074974
Drug: Supportive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Therapy
Trial: 17884442
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg extract of green and black tea per day for 3 months